Leuprolide: Uses, Mechanism, and Reported Side Effects

Men diagnosed with advanced prostate cancer often want to understand how hormone-based therapy actually works before starting treatment. Leuprolide is one of the most established options in this category, with a long record of clinical use and study.

Key takeaways

• Leuprolide is a GnRH agonist that lowers testosterone and estrogen production with continuous use.
• It is FDA-approved for advanced prostate cancer under the brand name Vabrinty.
• More than 500 registered trials have studied leuprolide across various formulations and comparisons.
• The most frequently reported issues in safety databases involve hot flushes, fatigue, and injection-related product problems.
• Leuprolide's effects on hormone suppression are reversible after treatment is stopped.

What Leuprolide Is

Leuprolide acetate belongs to a class of medicines called GnRH (gonadotropin releasing hormone) agonists. When given continuously, it suppresses the body's normal signaling for testosterone and estrogen production. The label describes an initial period of hormone stimulation followed by sustained suppression of testicular and ovarian steroid production. This suppressive effect reverses once the drug is discontinued.

What Leuprolide Is Approved For

Leuprolide, marketed as Vabrinty, is approved for the treatment of advanced prostate cancer. As a GnRH agonist, it works by reducing the testosterone that can fuel prostate cancer growth. The current label does not carry a boxed warning.

What The Evidence Shows

Leuprolide has been studied in 544 registered clinical trials, reflecting decades of research across multiple conditions and formulations. A phase 4 trial compared switching patients from monthly or quarterly Zoladex to semiannual Eligard, both leuprolide-based products, and this study has completed. A separate phase 2 trial examined a related GnRH agonist compound for endometriosis and also reached completion, illustrating the broader research interest in this drug class beyond prostate cancer alone.

Reported Side Effects

Reports submitted to safety databases are counts of adverse event reports, not confirmed rates of incidence or proof that leuprolide caused the event. The most commonly reported reaction is hot flush, with over 9,500 reports, a known effect of hormone suppression. Fatigue and injection site pain are also frequently reported. A substantial share of reports involve product use issues, including preparation errors, syringe problems, and device leakage, pointing to administration-related concerns alongside the physiological effects of the drug. Reports of death have also been submitted to these databases, though such reports do not establish that leuprolide was the cause.